Earnings summaries and quarterly performance for Edwards Lifesciences.
Executive leadership at Edwards Lifesciences.
Bernard Zovighian
Detailed
Chief Executive Officer
CEO
AB
Annette Brüls
Detailed
Corporate Vice President, EMEACLA
DL
Daniel Lippis
Detailed
Corporate Vice President, Transcatheter Aortic Valve Replacement
DC
Daveen Chopra
Detailed
Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies
DB
Donald Bobo Jr
Detailed
Corporate Vice President, Strategy & Corporate Development
SU
Scott Ullem
Detailed
Chief Financial Officer
WM
Wayne Markowitz
Detailed
Senior Vice President, Surgical Structural Heart
Board of directors at Edwards Lifesciences.
Research analysts who have asked questions during Edwards Lifesciences earnings calls.
DR
David Roman
Goldman Sachs Group Inc.
5 questions for EW
Also covers: ABT, BAX, BDX +18 more
RM
Robert Marcus
JPMorgan Chase & Co.
5 questions for EW
Also covers: ABT, BAX, BDX +21 more
Travis Steed
Bank of America
5 questions for EW
Also covers: ABT, AXNX, BAX +19 more
Vijay Kumar
Evercore ISI
5 questions for EW
Also covers: A, ABT, AVTR +21 more
Joanne Wuensch
Citigroup Inc.
3 questions for EW
Also covers: ABT, BAX, BDX +18 more
LB
Larry Biegelsen
Wells Fargo & Company
3 questions for EW
Also covers: ABT, ALC, AXNX +24 more
MT
Matthew Taylor
Jefferies
3 questions for EW
Also covers: ALUR, BDX, CQP +18 more
AP
Anthony Petrone
Mizuho Group
2 questions for EW
Also covers: ADMA, ALC, BSX +22 more
Chris Pasquale
Nephron Research LLC
2 questions for EW
Also covers: ALC, AXGN, BSX +7 more
LB
Lawrence Biegelsen
Wells Fargo
2 questions for EW
Also covers: ABT, ALC, BAX +16 more
Matthew Miksic
Barclays PLC
2 questions for EW
Also covers: ABT, ATEC, BAX +15 more
Matt Miksic
Barclays Investment Bank
2 questions for EW
Also covers: ABT, ATEC, BAX +14 more
MT
Matt Taylor
Jefferies & Company Inc.
2 questions for EW
Also covers: BAX, BIO, DXCM +10 more
Patrick Wood
Morgan Stanley
2 questions for EW
Also covers: ALC, BDX, BLCO +17 more
PC
Pito Chickering
Deutsche Bank
2 questions for EW
Also covers: ACHC, AHCO, AVAH +18 more
Adam Maeder
Piper Sandler Companies
1 question for EW
Also covers: ABT, AXNX, GKOS +13 more
Christopher Pasquale
Nephron Research
1 question for EW
Also covers: ALC, AXGN, BSX +12 more
DA
Danielle Antalffy
UBS Group AG
1 question for EW
Also covers: ABT, ATRC, BAX +15 more
FW
Frederick Wise
Stifel
1 question for EW
Also covers: AORT, ATRC, AVNS +13 more
Recent press releases and 8-K filings for EW.
Edwards Lifesciences receives FDA approval for SAPIEN M3 transseptal mitral valve system
EW
Product Launch
- FDA approves the SAPIEN M3 transcatheter mitral valve replacement (TMVR) system, making it the first transseptal transcatheter therapy for symptomatic moderate-to-severe or severe mitral regurgitation in patients unsuitable for surgery or transcatheter edge-to-edge repair.
- One-year data from the ENCIRCLE pivotal trial (299 patients) demonstrated 95.7% MR elimination (≤0/1 +) and meaningful improvements in symptoms and quality-of-life.
- The system employs a fully percutaneous, 29F transseptal steerable guide sheath via the femoral vein for dock and valve delivery.
- SAPIEN M3 received CE Mark in April 2025, becoming the world’s first approved transfemoral TMVR system and broadening Edwards’s transcatheter mitral and tricuspid therapy portfolio.
3 hours ago
Edwards Lifesciences: Transcatheter Valve Market to Reach USD 19.98B by 2033
EW
- The global transcatheter heart valve replacement market is projected to grow from USD 6.40 billion in 2025 to USD 19.98 billion by 2033, at a CAGR of 15.32% during 2026–2033.
- The U.S. market is estimated at USD 2.65 billion in 2025 and is expected to reach USD 8.24 billion by 2033, growing at a 15.24% CAGR driven by advanced infrastructure and regulatory approvals.
- Growth drivers include an aging population, increasing adoption of minimally invasive procedures, favorable reimbursement policies, and rapid technological advancements in valve design.
6 days ago
Edwards Life Sciences sets 2025 guidance and outlines long-term growth strategy
EW
Guidance Update
New Projects/Investments
- Edwards expects 8%–10% total sales growth in 2025, with TAVR up 5%–7%, TMTT growing 50%–60% to over $500 million, and EPS of $2.40–$2.50.
- For 2026 and beyond, the company targets ~10% average annual revenue growth and double-digit EPS growth, driven by catalysts such as early TAVR approval in mid-2025, the PROGRESS trial readout in 2026, and the U.S. launch of SAPIEN M3 in early 2026; TMTT is aimed at $2 billion by 2030.
- The strategic focus is on structural heart with three 2025 growth drivers (TAVR, mitral, tricuspid) and two emerging areas (aortic regurgitation and heart failure). The pipeline features Gen 5 SAPIEN Ultra, EVOQUE and SAPIEN M3, supported by $1 billion internal and $1.6 billion external R&D investments, over 10,000 patents, and ongoing category leadership.
Dec 4, 2025, 1:30 PM
Edwards Lifesciences provides 2026 financial outlook at Investor Day 2025
EW
Guidance Update
Share Buyback
New Projects/Investments
- Edwards Lifesciences projects 2026 sales of $6.4 – $6.8 billion (8 – 10% growth) and adjusted EPS of $2.80 – $2.95 (~11% growth at midpoint).
- TAVR business expected to grow 6 – 8% in 2026, TMTT sales of $740 – $780 million (targeting $2 billion by 2030), and surgical segment mid-single-digit growth.
- Ongoing R&D investments to drive innovation, targeting ~17% of sales in 2026, with 40% allocated to scientific evidence and 35% to new product development.
- Strong capital deployment with ~$280 million CAPEX in 2026 , a remaining $2 billion share repurchase authorization, and opportunistic buybacks driving shares outstanding to 580 – 585 million.
Dec 4, 2025, 1:30 PM
Edwards Lifesciences unveils 2025 guidance and long-term structural heart strategy
EW
Guidance Update
Product Launch
New Projects/Investments
- 2025 financial guidance: total company sales growth of 8%–10%, TAVR growth 5%–7%, Transcatheter Mitral & Tricuspid Therapies (TMTT) sales growth 50%–60%, and EPS of $2.40–$2.50.
- Long-term targets: average annual sales growth of 10% and double-digit EPS growth from 2026 onward, driven by catalysts including Early TAVR approval (mid-2025), PROGRESS trial readout (2026), and U.S. launch of SAPIEN M3 (2026).
- TMTT portfolio expansion: four pillars—PASCAL repair, EVOQUE replacement, SAPIEN M3 mitral replacement, and PASCAL tricuspid—aiming for $500 m+ in 2025 and $2 b by 2030.
- Strategic shift to structural heart: completed sale of Critical Care, focusing exclusively on structural heart; invested $1 b internally and $1.6 b externally in R&D (2024) and expanding supply chain with a new Spain facility.
Dec 4, 2025, 1:30 PM
Edwards Lifesciences outlines structural heart-focused growth strategy at Investor Day 2025
EW
Guidance Update
Product Launch
- CEO Bernard Zovighian positions 2025 as the first year as a solely structural heart company, citing sale of critical care and four 2024 acquisitions to concentrate on TAVR, mitral, tricuspid, plus emerging structural heart failure and aortic regurgitation opportunities.
- 2025 guidance: total company sales growth of 8–10%, 5–7% TAVR growth, 50–60% TMTT expansion to $500 M+, and $2.40–$2.50 EPS; targeting 10% average annual sales growth and double-digit EPS growth for 2026+.
- Key upcoming catalysts include mid-2025 approval for early TAVR, PROGRESS trial readout in 2026, European launch of SAPIEN M3 in mid-2025 and US in H1 2026, plus ongoing PASCAL/EVOQUE adoption.
- CFO underscores focus on strong organic growth, maintaining 78–79% gross margins in 2025, driving 50–100 bps of annual operating margin expansion from 2026, and strategic capital deployment through share buybacks, CapEx investments, and selective structural heart M&A.
Dec 4, 2025, 1:30 PM
Edwards Lifesciences highlights market potential of EchoSolv AS after AHA 2025 data
EW
Product Launch
- Two studies presented at AHA Scientific Sessions 2025 reveal significant gaps in standard‐of‐care for severe aortic stenosis (AS) and demonstrate EchoSolv AS’s potential to improve patient outcomes.
- In an investigator‐initiated analysis of 30,878 echocardiograms, EchoSolv AS outperformed cardiologists in identifying severe AS, particularly in women, improving the male-to-female diagnosis ratio from 2.2:1 to 1.1:1.
- A NEDA study of 1.18 million patients showed only 36% of women and 45% of men with moderate-to-severe AS received intervention, underscoring a critical treatment gap.
- EchoSolv AS has FDA clearance and has been validated across the United States and Australia, offering the potential to reduce diagnostic delays and optimize timing of valve interventions.
Nov 12, 2025, 9:05 PM
Edwards Lifesciences reports Q3 2025 results
EW
Earnings
Guidance Update
CFO Change
- Q3 sales rose 12.6% to $1.55 billion, driven by double-digit growth in structural heart therapies (constant currency).
- Full-year sales growth guidance raised to the high end of 9–10%, and EPS guidance lifted to $2.56–$2.62.
- Third-quarter TMTT sales jumped 53% to $144 million, while surgical sales increased 5.6% to $258 million.
- Reported adjusted EPS of $0.67 (GAAP EPS $0.50) and issued Q4 guidance for $1.51–$1.59 billion in sales and $0.58–$0.64 adjusted EPS.
- CFO Scott Ullem to transition out by mid-2026, remaining as strategic advisor during the succession.
Oct 30, 2025, 9:00 PM
Edwards Lifesciences reports Q3 2025 results
EW
Earnings
Guidance Update
Share Buyback
- Net sales of $1.55 billion, up 14.7% year-over-year (12.6% adjusted) in Q3 2025.
- TAVR sales grew 12.4% to $1.15 billion (10.6% constant currency); TMTT sales reached $145.2 million.
- GAAP EPS of $0.50; adjusted EPS of $0.67 in Q3 (adjusted operating margin 27.5%).
- Raised 2025 guidance: total sales growth to 9–10%, TAVR to 7–8%, and adjusted EPS to $2.56–2.62; share repurchase authorization increased to $2.1 billion.
Oct 30, 2025, 8:18 PM
Edwards Lifesciences reports Q3 2025 results
EW
Earnings
Guidance Update
Share Buyback
- Q3 2025 total sales rose 14.7% year-over-year to $1.553 billion (12.6% adjusted), driven by TAVR sales growth of 12.4% to $1.15 billion and a 59.3% increase in TMTT to $145.2 million
- GAAP EPS of $0.50 and adjusted EPS of $0.67, with an adjusted operating margin of 27.5% in the quarter
- Raised 2025 full-year guidance: total sales growth to the high end of 9–10%, TAVR growth to 7–8%, and adjusted EPS to $2.56–2.62
- Q3 R&D expenses increased to $281 million; ended the quarter with $3.0 billion in cash, $0.6 billion in debt, and an expanded share repurchase authorization of $2.1 billion
Oct 30, 2025, 8:13 PM
Quarterly earnings call transcripts for Edwards Lifesciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more